FDA OK for Pivekimab Sunirine-pvzy (Decnupaz)

Key Takeaways

• Approval date: May 27, 2026, for adult BPDCN based on Phase 1/2 CADENZA (NCT03386513).
• Newly diagnosed cohort (n=33): 69.7% composite complete response; median DOR 9.7 months; 39.4% proceeded to transplant.
• Relapsed/refractory cohort (n=51): 15.7% composite CR; median DOR 9.2 months.
• Boxed warning for hepatotoxicity including VOD; Breakthrough Therapy designation for R/R BPDCN dated October 2020.

What is Decnupaz and who is it for?

Decnupaz (pivekimab sunirine-pvzy) is a CD123-targeting ADC. The payload is an indolinobenzodiazepine pseudodimer that alkylates DNA and causes single-strand breaks, triggering apoptosis in CD123-expressing cells.

BPDCN is an ultra-rare aggressive hematologic malignancy that often presents with skin lesions and can involve bone marrow, nodes, and CNS. AbbVie said the product is the first and only ADC approved for BPDCN that is initiated outpatient, in its May 27, 2026 PR Newswire release.

How strong were the CADENZA efficacy data?

CADENZA is a Phase 1/2 multicenter open-label study of pivekimab sunirine in CD123-positive hematologic malignancies, including BPDCN. AbbVie reported clinically meaningful responses in newly diagnosed patients without CNS involvement.

• n=33 newly diagnosed: 69.7% composite CR; median DOR 9.7 months; 13/33 (39.4%) to transplant
• n=51 relapsed/refractory: 15.7% composite CR; median DOR 9.2 months; 6/51 (11.8%) to transplant
• Trial registry: NCT03386513
• Breakthrough Therapy designation: October 2020 (R/R BPDCN)
• Orphan designation for BPDCN recorded November 17, 2020 in FDA OOPD records

Registry status is on ClinicalTrials.gov NCT03386513. Peer-reviewed CADENZA results appear in the Journal of Clinical Oncology (2026).

What safety risks must clinicians manage?

Decnupaz has a boxed warning for hepatotoxicity, including hepatic veno-occlusive disease that can be life-threatening. Prescribing information also warns on infusion-related reactions, edema, sulfite allergic reactions, and embryo-fetal toxicity.

Most common adverse reactions (≥20%) were edema, fatigue, musculoskeletal pain, hemorrhage, infusion-related reactions, nausea, and diarrhea. Liver labs before each dose are part of labeled monitoring. Broader ADC class context sits with FDA Drugs safety communications practices.

Why does this matter for AbbVie’s oncology strategy?

AbbVie framed Decnupaz as its first ADC approved for blood cancer, expanding beyond solid-tumor ADC partnerships into a rare leukemia niche where intensive chemo and transplant still dominate frontline care. For competitors, the outpatient initiation claim is a practical differentiator versus inpatient-heavy regimens.

Commercial upside is capped by BPDCN incidence—typically older adult men aged about 60–70—but rare-disease pricing and transplant bridge use can still move franchise economics.

What remains unproven?

CADENZA is not a large randomized Phase 3 versus contemporary standards. Relapsed/refractory composite CR was 15.7%, so expectations for heavily pretreated patients should stay modest. Long-term survival and real-world VOD rates after approval are not yet established in post-marketing datasets.

How should formulary and pathway teams prepare?

Pathway committees should place pivekimab sunirine-pvzy beside intensive induction and transplant algorithms for newly diagnosed BPDCN, with clear stop rules if liver tests worsen. Outpatient initiation can reduce bed days, but infusion-reaction observation still needs staffing for at least four hours after the first dose, as labeled. Sulfite allergy screening should be routine before the first infusion.

Payers will ask for CADENZA cohort definitions—especially exclusion of active CNS disease—and for documentation of prior therapies in the relapsed setting. Contracting teams should also track orphan exclusivity clocks tied to the November 17, 2020 orphan designation and the May 27, 2026 approval date.

Related NovaPharma coverage

• BPDCN disease profile
• AbbVie company profile
• AbbVie Cerevel $8.7B neuroscience deal

Frequently Asked Questions

Primary Sources

1. PR Newswire: FDA approves Decnupaz
2. ClinicalTrials.gov NCT03386513 (CADENZA)
3. JCO: Pivekimab sunirine in BPDCN
4. FDA OOPD orphan designation listing